
Spain · Information technology & services startup
Seqera is a bioinformatics software company based in Barcelona, Spain, founded in 2018 by Paolo Di Tommaso and Evan Floden.
Funding reportedLast round: Series A
Seqera is a bioinformatics software company based in Barcelona, Spain, founded in 2018 by Paolo Di Tommaso and Evan Floden.
As the commercial steward of the open-source workflow orchestration ecosystem Nextflow, Seqera focuses on providing enterprise-grade software and services to manage data-intensive computations in life sciences. The company operates in Barcelona, New York, and London, employing approximately 51 to 200 people. Seqera offers a range of professional services to help life-science organizations scale their genomics and AI workloads. These include enterprise workflow orchestration, professional support and consulting, hybrid data access solutions, and enterprise governance tools. The Seqera Platform integrates these services, featuring components like Seqera Pipelines for workflow deployment, Seqera Containers for container management, and Seqera Studios for interactive data analysis. Seqera's technology is designed to facilitate scalable and reproducible scientific data analysis across various computing environments, making it a valuable resource for pharmaceutical companies, research institutions, and healthcare providers.
Funding, as reported
What they build
Known for
workflow containerizationhealth carecloud pipeline orchestrationbioinformatics softwarecontainer supportprofessional servicesseqera cloudcollaborative research toolscloudgenomic datacontainerizationcomputer & network securitygenomic data analysisreactive programmingeducation resourcespipeline troubleshooting
Built with from their website
Google MapsGoogle CalendarPayFitAmazon SESGoogle Tag ManagerOneTrust Tech Risk & ComplianceEnvoyHREF LangAtlassianPWA
FlowYouTubeGoogle WorkspaceCloudFlareGemViewport MetaAmazon Simple Email ServiceHubspot
Add your raise, your deck and your story, and put Seqera in front of investors. Or tell us what we have wrong.